Skip to main content

Advertisement

Log in

Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels

  • SHORT COMMUNICATION
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. Methods: A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen and metabolites were measured by high-performance liquid chromatography and compared with levels determined in 31 patients with advanced breast cancer at the steady state at a daily dose of 30 mg of tamoxifen. Results: Serum and urine levels (24-h values) of tamoxifen and metabolites were lower (P<0.05) after a loading dose than at the steady state. The difference was most pronounced for the metabolites, whereas the tamoxifen loading-dose level was near the steady state. Conclusion: Tamoxifen steady state can be reached in 1–2 days by the administration of a loading dose of 160 mg of tamoxifen for 2 days. Tamoxifen metabolite steady-state levels are reached regularly after 4 or more weeks during application of a loading dose. Very little tamoxifen or metabolites are excreted into the urine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 17 December 1997 / Accepted: 2 June 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Vos, D., Slee, P., Briggs, R. et al. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels. Cancer Chemother Pharmacol 42, 512–514 (1998). https://doi.org/10.1007/s002800050854

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002800050854

Navigation